Robert P Giugliano

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Association of hemoglobin levels with clinical outcomes in acute coronary syndromes
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 111:2042-9. 2005
  2. ncbi Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA, USA
    Lancet 380:2007-17. 2012
  3. ncbi Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial
    Robert P Giugliano
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2398-407. 2007
  4. ncbi Early versus delayed, provisional eptifibatide in acute coronary syndromes
    Robert P Giugliano
    TIMI Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 360:2176-90. 2009
  5. ncbi 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians
    Robert P Giugliano
    TIMI Study Group
    Nat Clin Pract Cardiovasc Med 2:114-5. 2005
  6. ncbi The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
  7. ncbi Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    Robert P Giugliano
    Cardiovascular Medicine, TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Eur Heart J 31:2103-10. 2010
  8. ncbi Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1251-60. 2003
  9. ncbi Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discu
    Robert P Giugliano
    Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Fl Offices, Boston, MA 02115, USA
    J Interv Cardiol 24:119-36. 2011
  10. ncbi Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 52:914-20. 2008

Detail Information

Publications85

  1. ncbi Association of hemoglobin levels with clinical outcomes in acute coronary syndromes
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 111:2042-9. 2005
    ..In the setting of an acute coronary syndrome (ACS), anemia has the potential to worsen myocardial ischemia; however, data relating anemia to clinical outcomes in ACS remain limited...
  2. ncbi Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA, USA
    Lancet 380:2007-17. 2012
    ..We therefore assessed the efficacy, safety, and tolerability of AMG 145, a human monoclonal IgG2 antibody against PCSK9, in stable patients with hypercholesterolemia on a statin...
  3. ncbi Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial
    Robert P Giugliano
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2398-407. 2007
    ..We sought to evaluate the safety and efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-segment elevation acute coronary syndrome (nSTE-ACS)...
  4. ncbi Early versus delayed, provisional eptifibatide in acute coronary syndromes
    Robert P Giugliano
    TIMI Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 360:2176-90. 2009
    ..Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown...
  5. ncbi 2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians
    Robert P Giugliano
    TIMI Study Group
    Nat Clin Pract Cardiovasc Med 2:114-5. 2005
  6. ncbi The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with n
    Robert P Giugliano
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:994-1002. 2005
    ..However, the guidelines are not explicit regarding the timing of initiation of GpIIb-IIIa antagonists, and there is marked variation in clinical practice regarding their use...
  7. ncbi Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    Robert P Giugliano
    Cardiovascular Medicine, TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Eur Heart J 31:2103-10. 2010
    ..To evaluate the association of bleeding with mortality in ST-elevation myocardial infarction (STEMI)...
  8. ncbi Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial
    Robert P Giugliano
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1251-60. 2003
    ..The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI)...
  9. ncbi Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discu
    Robert P Giugliano
    Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Fl Offices, Boston, MA 02115, USA
    J Interv Cardiol 24:119-36. 2011
    ..Each author held primary responsibility for the writing and editing of his or her section, and participated in the editing of the entire manuscript...
  10. ncbi Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 52:914-20. 2008
    ..This study sought to determine whether the benefit of intensive lipid-lowering therapy (LLT) is dependent on baseline low-density lipoprotein cholesterol (LDL-C)...
  11. ncbi Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  12. ncbi Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  13. ncbi Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  14. ncbi Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  15. ncbi Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  16. ncbi Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    JACC Cardiovasc Interv 5:927-35. 2012
    ....
  17. ncbi The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  18. ncbi Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 95:337-42. 2005
    ..2, p = 0.045). CLC is independently associated with indexes of poorer epicardial flow and a higher incidence of adverse clinical outcomes after fibrinolytic administration in patients who have ST-elevation myocardial infarction...
  19. ncbi Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  20. ncbi Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
    C Michael Gibson
    TIMI Study Group and the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 110:679-84. 2004
    ....
  21. ncbi Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Am Heart J 147:847-52. 2004
    ....
  22. ncbi Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, and TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, USA
    Am J Cardiol 95:224-7. 2005
    ..043). In multivariate analyses, angiographically evident thrombus was associated with higher corrected TIMI frame counts and worsened myocardial perfusion independent of clinical and angiographic covariates, including TIMI grade 3 flow...
  23. ncbi The year in non-ST-segment elevation acute coronary syndromes
    Robert P Giugliano
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:386-95. 2006
  24. ncbi Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome
    Raphaelle Dumaine
    Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Hypertens (Greenwich) 8:315-22. 2006
    ..45, 95% CI 1.03-2.06; p=0.036 at 30 days). It was concluded that chronic hypertension remains an independent marker for major short- and long-term cardiac adverse outcomes after non-ST-segment elevation acute coronary syndrome...
  25. ncbi Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality
    C Michael Gibson
    TIMI Study Chairman s Office, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Am Coll Cardiol 42:1535-43. 2003
    ..We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis...
  26. ncbi Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Drugs 69:1433-43. 2009
    ....
  27. ncbi Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Circulation 123:2681-9. 2011
    ....
  28. ncbi A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  29. ncbi Identification of patients at high risk for death and cardiac ischemic events after hospital discharge
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 143:966-70. 2002
    ..Patients with unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) remain at risk for death and cardiac ischemic events after being discharged from the hospital...
  30. ncbi Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:980-7. 2004
    ....
  31. ncbi Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women's Hospital, Boston, Mass, USA
    Am Heart J 148:336-40. 2004
    ..Partial or full angiographic perfusion scores are associated with a halving of infarct size, and no patients with full angiographic perfusion died...
  32. ncbi The year in non-ST-segment elevation acute coronary syndrome
    Robert P Giugliano
    TIMI Study Group, Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1386-95. 2007
  33. ncbi ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy
    Deepak Thomas
    Department of Nuclear Cardiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:1-10. 2009
    ....
  34. ncbi Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Am Coll Cardiol 42:7-16. 2003
    ..We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years...
  35. ncbi Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Thromb Thrombolysis 17:177-84. 2004
    ..8, p = 0.02) and 30-day congestive heart failure (OR 4.4, p = 0.02). In STEMI, angiographic indices of incomplete reperfusion are associated with an elevated LVEDP, and elevated LVEDP is associated with adverse clinical outcomes...
  36. ncbi Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials)
    Shaheeda Ahmed
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and the Department of Medicine, Harvard Medical School, USA
    J Thromb Thrombolysis 21:119-29. 2006
    ..37, 2.83, and 2.92 respectively, p < 0.001 for all). These robust estimates can be used as benchmarks to monitor the efficacy and safety of therapies in ongoing and newly completed clinical trials...
  37. ncbi Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Am Coll Cardiol 45:357-62. 2005
    ....
  38. ncbi Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice
    Deepak Thomas
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 8:12-9. 2009
    ..In this article, we discuss the findings of this major trial, review previously published literature that compares the 2 medications, and provide a clinical context for the potential role of prasugrel in practice...
  39. ncbi Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction
    Hung Q Ly
    Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 95:383-6. 2005
    ..44, 95% confidence interval 0.23 to 0.85, p = 0.014)...
  40. ncbi Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials
    C Michael Gibson
    Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 25:1998-2005. 2004
    ..To determine the association of glomerular filtration rate (GFR) with clinical outcomes in the setting of non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  41. ncbi Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial
    Quynh A Truong
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am Heart J 157:673-9.e1. 2009
    ..We sought to evaluate whether TRI was predictive of long-term mortality and clinical events...
  42. ncbi Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 44:783-9. 2004
    ..We sought to evaluate a simple risk index based on age and vital signs in a community sample of patients with ST-segment elevation myocardial infarction (STEMI)...
  43. ncbi Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction
    C Michael Gibson
    Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 94:108-11. 2004
    ..In a multivariate model, type C lesion complexity remained associated with an increased 30-day mortality rate...
  44. ncbi The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 25:1139-45. 2004
    ....
  45. ncbi Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Minang P Turakhia
    Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California, USA
    Am J Cardiol 94:1406-10. 2004
    ..A higher platelet count is independently associated with the presence of residual thrombus in the infarct-related artery after administration of fibrinolytic therapy, even after multivariate adjustment...
  46. ncbi Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy
    Payal Kohli
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Clin Cardiol 35:385-91. 2012
    ....
  47. ncbi Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture
    C Michael Gibson
    TIMI Study Group, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    J Thromb Thrombolysis 15:189-96. 2003
    ....
  48. ncbi Effect of rescue or adjunctive percutaneous coronary intervention of the culprit artery after fibrinolytic administration on epicardial flow in nonculprit arteries
    Graham S Gardner
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:178-81. 2004
    ..The corrected TIMI frame count in nonculprit arteries improved by 3.4 +/- 13.4 frames after percutaneous coronary intervention but remained significantly slower than flow in normal arteries...
  49. ncbi Day 1 care in patients with non-ST-segment elevation myocardial infarction
    Deepak Thomas
    Brigham and Women s Hospital, Nuclear Cardiology, Boston, MA, USA
    Cardiovasc Revasc Med 11:41-51. 2010
    ..In this article, we focus on management of patients with NSTEMI during the first 24 h of presentation and present a clinical scenario to illustrate the current guidelines-based management strategy...
  50. ncbi Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Cardiol 155:424-9. 2012
    ..We examined whether there were differential effects of prasugrel compared with clopidogrel in the multinational TRITON-TIMI 38 study...
  51. ncbi Perspectives on the 2009 focused updates on the management of ST-segment elevation myocardial infarction and percutaneous intervention
    Deepak Thomas
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 9:126-33. 2010
    ....
  52. ncbi The year in non-ST-segment elevation acute coronary syndromes
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 46:906-19. 2005
  53. ncbi Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1646-54. 2005
    ..Pilot studies have suggested that antibiotic treatment may reduce the risk of cardiovascular events...
  54. ncbi Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial
    David A Morrow
    Cardiovascular Division and TIMI Study Group, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 40:71-7. 2002
    ....
  55. ncbi Prior aspirin use and outcomes in acute coronary syndromes
    Jonathan D Rich
    Section of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    J Am Coll Cardiol 56:1376-85. 2010
    ..The purpose of this study was to determine whether patients taking aspirin before an acute coronary syndrome (ACS) are at higher risk of recurrent events or mortality...
  56. ncbi The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes
    Shaheeda Ahmed
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, USA Department of Medicine, Harvard Medical School, USA
    Int J Cardiol 131:105-12. 2008
    ..To assess the effect of renal impairment (RI) and diabetes (DM) on outcomes in non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  57. ncbi Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes
    Robert W Yeh
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 100:1734-8. 2007
    ..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH...
  58. ncbi Association of the Fibonacci Cascade with the distribution of coronary artery lesions responsible for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Chairman's Office, The Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 92:595-7. 2003
    ....
  59. ncbi Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 160:635-41. 2010
    ..Edoxaban is a selective and direct factor Xa inhibitor that may provide effective, safe, and more convenient anticoagulation...
  60. ncbi Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-elevation myocardial infarction
    Larry A Allen
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Am J Cardiol 93:1218-22. 2004
    ..In firmly establishing the benefit of consensus guidelines, the foundation is set for efforts to improve practitioner compliance with these standards...
  61. ncbi Comparison of long-term mortality across the spectrum of acute coronary syndromes
    Larry A Allen
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 151:1065-71. 2006
    ..This mortality excess for MMD/NSTEMI was associated with more comorbid conditions and decreased use of basic therapies for ACS. After controlling for baseline differences, STEMI patients had the highest mortality...
  62. ncbi Usefulness of the TIMI Risk Index in predicting short- and long-term mortality in patients with acute coronary syndromes
    Leonard Ilkhanoff
    Cardiovascular Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Am J Cardiol 96:773-7. 2005
    ..These results verify the utility of the Risk Index in unselected patients with STEMI, broaden its application to other types of ACSs, and extend its utility to stratification of long-term mortality risk...
  63. ncbi Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention
    Graham C Wong
    TIMI Study Group, Brigham and Women's Hospital, Boston, Mass 02115, USA
    JAMA 289:331-42. 2003
    ..In addition, they show promise as a safe and efficacious antithrombotic agent for PCI. However, further study is warranted to define the benefit of LMWHs in certain high-risk subgroups before their use can be universally recommended...
  64. ncbi Effectiveness and safety of percutaneous coronary intervention after fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Suzanne J Baron
    Department of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Am J Cardiol 107:1001-9. 2011
    ....
  65. ncbi Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 156:826-32. 2008
    ....
  66. ncbi Management of ST-segment elevation myocardial infarction: Comparison of the updated guidelines from North America and Europe
    Deepak Thomas
    Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 158:695-705. 2009
    ....
  67. ncbi Antithrombotics in acute coronary syndromes
    Marc P Bonaca
    TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:969-84. 2009
    ..In addition to reviewing existing agents, we take a look forward at the most promising new antithrombotics currently in late-stage clinical development and their potential role in the context of ACS management...
  68. ncbi Selecting the best reperfusion strategy in ST-elevation myocardial infarction: it's all a matter of time
    Robert P Giugliano
    The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 108:2828-30. 2003
  69. ncbi Improving antithrombotic treatment in patients after myocardial infarction
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, M A02115, USA
    Lancet 362:757. 2003
  70. ncbi Prognostic value of SPECT myocardial perfusion imaging in patients with elevated cardiac troponin I levels and atypical clinical presentation
    Sharmila Dorbala
    Division of Nuclear Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Nucl Cardiol 14:53-8. 2007
    ..We determined the prognostic value of myocardial perfusion imaging (MPI) in patients with atypical clinical presentations and unexpected elevation of cardiac troponin I (cTnI) levels...
  71. ncbi Antithrombotics in acute coronary syndromes: updates from the past year
    Marc Bonaca
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
    Curr Treat Options Cardiovasc Med 12:84-99. 2010
    ..Incremental updates to guideline recommendations from established expert groups will be important in providing guidance...
  72. ncbi Meta-analysis of corticosteroid treatment in acute myocardial infarction
    Gregory R Giugliano
    Division of Clinical Biometrics, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 91:1055-9. 2003
    ..72 to 1.26), respectively. Two tests revealed no evidence for publication bias. Thus, the review of available clinical studies demonstrated no harm and a possible mortality benefit of corticosteroids in acute myocardial infarction...
  73. ncbi Predictors of long-term mortality after hospitalization for primary unstable angina pectoris and non-ST-elevation myocardial infarction
    Donald M Lloyd-Jones
    Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Am J Cardiol 92:1155-9. 2003
    ..Easily obtained clinical covariates provide excellent prediction of long-term mortality up to 10 years after hospitalization for primary UAP and NSTEMI...
  74. ncbi Baseline troponin in acute coronary syndromes managed invasively
    Robert P Giugliano
    Am J Med 117:963-5. 2004
  75. ncbi Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction
    Craig R Walsh
    Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am Heart J 144:1003-11. 2002
    ..CONCLUSIONS: Elevated serum creatinine at presentation is associated with 1-year mortality after acute myocardial infarction. Further study is needed to optimize treatment after myocardial infarction in this high-risk group...
  76. ncbi Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction
    Amir Kashani
    Rochester General Hospital, Rochester, New York, USA
    Am J Cardiol 95:228-33. 2005
    ....
  77. ncbi Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction
    Ajay J Kirtane
    J Am Coll Cardiol 45:321-3. 2005
  78. ncbi U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction
    Duane S Pinto
    J Am Coll Cardiol 46:178-80. 2005
  79. ncbi Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy)
    Robert H Christenson
    Pathology Department, University of Maryland Medical System, Baltimore, Maryland, USA
    Am J Cardiol 92:598-600. 2003
    ..These findings suggest that prodromal unstable angina is an important physiologic marker that should be routinely collected for risk stratification...
  80. ncbi Low-molecular-weight heparins for the treatment of acute coronary syndromes
    Graham C Wong
    Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
    Semin Vasc Med 3:391-402. 2003
    ..Larger clinical studies are needed to confirm the safety and efficacy of LMWH as an antithrombin for the treatment across the spectrum of ACS...
  81. ncbi Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe
    Deepak Thomas
    Department of Nuclear Cardiology, Brigham and Women s Hospital, Boston, MA, USA
    J Cardiovasc Pharmacol 51:425-33. 2008
    ..Because antiplatelet therapy is the cornerstone of management of patients with non-ST elevation acute coronary syndrome, health care providers should make themselves familiar with the new data and latest guideline recommendations...
  82. ncbi Management of ST-elevation myocardial infarction: an update on pharmacoinvasive recanalization
    Amir Kashani
    Section of Cardiology, Yale University School of Medicine, New Haven, Connecticut, USA
    Am J Cardiovasc Drugs 8:187-97. 2008
    ..We have linked current American College of Cardiology/American Heart Association Clinical Practice Guidelines to clinical data available in the literature...
  83. ncbi Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction
    Matthew T Roe
    Duke Clinical Research Institute and Division of Cardiology, Duke Medical Center, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 43:549-56. 2004
    ....
  84. ncbi The prognostic value of serum creatinine on admission in fibrinolytic-eligible patients with acute myocardial infarction
    Hans Peter Hobbach
    Division of Cardiology, Department of Internal Medicine, St Marien Krankenhaus Siegen, Germany
    J Thromb Thrombolysis 16:167-74. 2003
    ..Previous studies have demonstrated that impaired renal function is associated with unfavourable outcomes in patients with acute coronary syndromes and following percutaneous coronary intervention...
  85. ncbi Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)
    Abdallah G Rebeiz
    Duke Clinical Research Institute, Durham, North Carolina, USA
    Am J Cardiol 95:611-4. 2005
    ..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...